BioPharma Resources

Drug Trial Radar · NCT06989671

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

A Phase 2 Study of SYS6002 in Combination With JMT101 and Enlonstobart Injection in Participants With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

430

Planned (sponsor's estimate)

Start

Aug 30, 2025

Primary completion

Dec 30, 2027

Study completion Jul 30, 2028

Sponsor

Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • JMT101Drug

    JMT101 Q2W or Q3W, intravenous injection

  • SYS6002Drug

    SYS6002 Q2W or Q3W, intravenous injection

  • SG001Drug

    SG001 Q2W or Q3W, intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Incidence of Adverse Events (AEs)Time frame: Up to approximately 2 years
  3. Maximum Tolerated Dose (MTD)Time frame: Up to approximately 2 years
  4. Objective Response Rate (ORR)Time frame: Up to approximately 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.